Study of Dupilumab in Adult Participants With Active Eosinophilic Esophagitis (EoE)

Exclusion Criteria

• •1. Prior participation in a dupilumab (anti-IL-4R) clinical trial
• •2. Other causes of esophageal eosinophilia or the following diseases: hypereosinophilic syndromes, Churg-Strauss vasculitis, and eosinophilic gastroenteritis
• •3. History of achalasia, active Helicobacter pylori infection, Crohn's disease, ulcerative colitis, celiac disease, and prior esophageal surgery prior to screening
• •4. Any esophageal stricture unable to be passed with a standard, diagnostic, adult (9 to10 mm) upper endoscope or any critical esophageal stricture that requires dilation at screening
• •5. History of bleeding disorders or esophageal varices
• •6. Use of chronic aspirin, nonsteroidal agents, or anti-coagulants within 2 weeks prior to screening. Participants should not stop these agents solely to become eligible for entry into this study
• •7. Treatment with an investigational drug within 2 months or within 5 half-lives (if known), whichever is longer, prior to screening
• •8. Use of systemic corticosteroids within 3 months or swallowed topical corticosteroids within 3 months prior to screening
• •9. Use of inhaled (pulmonary or nasal) topical corticosteroids within 3 months prior to screening and during the study, except stable dose for at least 3 months prior to screening biopsy, which cannot be changed during the study
• •10. Treatment with oral immunotherapy (OIT) within 6 months prior to screening
• •11. Allergen immunotherapy unless on stable dose for at least 1 year prior to screening
• •12. Pregnant or breastfeeding women, or women planning to become pregnant or breastfeed during the study